Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Investors in ADMA Biologics urged to join class action over alleged misleading revenue claims.
ADMA
$8.62
-$0.25 -2.87%

Investors in ADMA Biologics urged to join class action over alleged misleading revenue claims.

Market News
30 Apr 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

The Rosen Law Firm has announced an investigation and is preparing a class action lawsuit on behalf of shareholders of ADMA Biologics, Inc. following allegations that the company issued misleading business information. The claims arose after a short seller report accused ADMA Biologics of channel stuffing to inflate revenue, causing the stock to drop 16.6% on March 24, 2026. Investors who purchased ADMA securities may be entitled to compensation through a contingency fee arrangement. The law firm encourages affected investors to contact them for more information and to join the class action.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App